[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"exercise-intolerance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:exercise-intolerance":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,54,97],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100627216","sports-shoes-and-the-six-minute-walk-test-in-copd-100627216",false,"NCT07445750","Sports Shoes and the Six-Minute Walk Test in COPD","Impact of High Biomechanical Efficiency Footwear on Six-Minute Walk Test Performance in Chronic Obstructive Pulmonary Disease (COPD): A Randomised Cross-Over Controlled Trial","ChaussePnee","Inclusion Criteria:\n\n* Age 18 or older\n* Diagnosed with COPD according to standard criteria\n* Severe to very severe airflow obstruction (FEV₁ \\\u003C 50% predicted, within 12 months)\n* Dyspnoea grade 3 or 4 on the mMRC scale\n* Currently hospitalised in the respiratory rehabilitation unit\n* Clinical indication for six-minute walk test\n* Provided written informed consent\n\nNon inlcusion Criteria:\n\n* Any respiratory condition other than COPD\n* Neurological, neuromuscular, orthopaedic or rheumatological conditions affecting gait or balance\n* Uncorrected visual or hearing impairment\n* Cognitive or psychiatric disorders interfering with instructions\n* Contraindications to exercise testing (e.g. unstable angina, recent myocardial infarction, severe uncontrolled hypertension, resting HR \\>120 bpm)\n* Pregnancy or breastfeeding\n* Inability to understand French\n* No health insurance coverage\n* Under legal protection (e.g. guardianship)\n* Participation in another interventional or randomised clinical trial\n* Habitual use of active sports shoes","ALL","18 Years",{"count":20,"type":21},75,"ESTIMATED","INTERVENTIONAL",[24],"NA","COPD: A Leading Cause of Respiratory Disability COPD, primarily linked to smoking, affects 3.5 million people in France and causes 15,000 deaths each year. It is a major source of disability, particularly due to dyspnoea, which affects one in three patients. Around 400,000 patients are registered under long-term conditions (ALD), and 200,000 receive home-based respiratory support. The most severe cases fall under the category of chronic respiratory failure-a term also applicable to other respiratory or neuromuscular diseases.\n\nWalking Exposes Physical Limitations In patients with respiratory failure, walking rapidly induces disabling dyspnoea, as it may represent their maximal effort. This severely limits autonomy and quality of life. To improve exercise tolerance, clinicians rely on pulmonary rehabilitation (exercise reconditioning, bronchodilators, oxygen therapy). When these measures are insufficient, mobility aids such as scooters or electric scooters may help, although they have limitations (cost, bulkiness, muscular deconditioning).\n\nThe Six-Minute Walk Test (6MWT): A Key Tool The 6MWT is a standardised test that assesses walking distance, dyspnoea, heart rate, and oxygenation. It is used to evaluate the severity and prognosis of respiratory failure and to measure response to treatment. It is integrated into prognostic indices and criteria for assessing the effectiveness of rehabilitation. The only non-standardised parameter remains the type of footwear worn.\n\nResearch Hypothesis Some so-called \"active\" sports shoes enhance walking by design-through cushioning, rocker soles, and rigid inserts-which store and return impact energy to assist propulsion. We hypothesise that wearing such shoes could improve walking performance in COPD patients, as reflected by a greater distance on the 6MWT. If confirmed, this simple and low-cost solution could meaningfully improve the daily lives of many patients.",[27,28,29],"Chronic Obstructive Pulmonary Disease (COPD)","Dyspnoea","Exercise Intolerance",[31,32,28,33,34,35,36,37,38,39,40],"COPD","Six-Minute Walk Test","Active Footwear","Gait","Biomechanics","Pulmonary Rehabilitation","Stair Climbing","Oxygen Saturation","Exercise Capacity","Respiratory Disability","NOT_YET_RECRUITING","2026-02-25",{"date":44,"type":45},"2026-03-03","ACTUAL",{"date":47,"type":21},"2026-04-01",{"date":49,"type":21},"2027-04-01",{"name":51,"class":52},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":66,"studyType":67,"phases":4,"briefSummary":68,"conditions":69,"keywords":75,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":53},"100605622","predictive-factors-of-response-to-phase-ii-cardiac-rehabilitation-in-heart-failure-with-reduced-ejection-fraction-100605622","NCT07164911","Predictive Factors of Response to Phase II Cardiac Rehabilitation in Heart Failure With Reduced Ejection Fraction","Prédiction Des réponses du Patient Porteur d'Une Insuffisance Cardiaque à Fraction d'éjection altérée à Une Phase II de réadaptation Cardiaque","PrédicRéa","Inclusion Criteria:\n\n* Heart failure with reduced ejection fraction \\\u003C 40%\n* NYHA functional class ≥ II\n* Clinically stable for at least 6 weeks\n* On optimized medical therapy for at least 6 weeks\n* Prescription for phase II cardiac rehabilitation\n* BMI between 20-30 kg·m-²\n* Physical activity level: sedentary or physically active but untrained\n* Signed informed consent to participate in the study\n* Affiliation to the French national health insurance system\n\nExclusion Criteria:\n\n* Contraindication to regular adapted physical activity\n* Uncontrolled arterial hypertension\n* Secondary respiratory disease such as emphysema or chronic obstructive pulmonary disease (COPD)\n* Secondary cardiovascular disease\n* Individuals under legal protection or deprived of liberty\n* Pregnant or breastfeeding women","40 Years","75 Years",{"count":65,"type":21},62,"1 Month","OBSERVATIONAL","Exercise intolerance, measured as peak oxygen consumption (VO₂peak) during exercise in patients with heart failure with reduced ejection fraction (HFrEF). Change in VO₂peak (ΔVO₂peak), which serves as a prognostic marker for HFrEF engaged in exercise based cardiac rehabilitation program (ExCR). Responders to ExCR generally show improved cardiac function but some patients with HFrEF do not respond to ExCR. VO₂peak depends on three major components of oxygen transport: Pulmonary (lungs), circulatory (heart and vessels) and skeletal muscle (oxygen utilization) functions. These physiological responses to ExCR may be influenced by epigenetic regulation, specifically the expression of circulating microRNAs (c-miRNAs).\n\nLinking non-invasive measurements and epigenetic markers could 1) identify which component of the oxygen transport chain is most impaired and 2) allow personalized interventions to maximize VO₂peak improvements.\n\nThe primary objective of this stidy is to assess the association between changes in VO₂peak during exercise training and circulating microRNA expression (miR-146a, miR-191, miR-23a, miR-140, miR-1, miR-21, miR-133a, miR-17-5p, miR-3200-3p).\n\nThe secondary objective is to examine the relationship between pulmonary, cardiovascular, and neuromuscular adaptations to exercise and circulating microRNA expression.",[70,71,72,73,29,74],"HFrEF - Heart Failure With Reduced Ejection Fraction","Cardiac Rehabilitation","Exercise Training","Exercise Adaptations","Exercise Intervention",[76,77,78,79,80,81,82,83,84,85],"Exercise-based cardiac rehabilitation in patients with reduced left ventricular ejection fraction","VO2peak","MicroRNA","Muscle Oxygenation","arterial stiffness","cardiac output","stroke volume","Oxygen alveolar-arterial gradient","alveolar ventilation","minute ventilation","RECRUITING","2025-12-08",{"date":89,"type":45},"2025-12-16",{"date":91,"type":45},"2025-11-25",{"date":93,"type":21},"2027-11-30",{"name":95,"class":96},"Centre Hospitalier de Corbie","OTHER_GOV",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":104,"sex":17,"minAge":18,"maxAge":62,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":53},"100609605","effects-of-breathing-training-and-nitrate-on-exercise-at-simulated-altitude-100609605","NCT07216755","Effects of Breathing Training and Nitrate on Exercise at Simulated Altitude","Impact of Respiratory Muscle Training and Nitrate Therapy on Exercise Tolerance in Simulated Altitude","Inclusion Criteria:\n\n* Healthy adults between 18 and 40 years old.\n\nRecreationally active (performing ≥3 hours of structured physical activity per week).\n\nNon-smokers for at least the past 6 months.\n\nFree from any known cardiovascular, pulmonary, metabolic, or neuromuscular disease as determined by health screening questionnaire and medical history.\n\nAble to perform cycle ergometer exercise to volitional fatigue.\n\nWilling to abstain from high-nitrate foods and supplements (e.g., beets, spinach, arugula) for 48 hours prior to each testing session.\n\nAble and willing to provide written informed consent and comply with all study procedures.\n\nExclusion Criteria:\n\n* Diagnosis of or history of heart disease, hypertension, diabetes, or chronic respiratory disorders (e.g., asthma, COPD).\n\nCurrent use of medications or supplements known to affect cardiovascular, metabolic, or respiratory function (e.g., beta-blockers, nitrates, stimulants).\n\nSmoking, vaping, or tobacco use within the past 6 months.\n\nKnown allergy or intolerance to beetroot products or nitrates.\n\nParticipation in another interventional research study within the past 30 days.\n\nPregnant or breastfeeding women.\n\nAny orthopedic or musculoskeletal limitation preventing safe exercise testing.\n\nFailure to meet inclusion criteria or inability to complete familiarization and baseline testing.",true,{"count":106,"type":21},80,[24],"This study investigates whether respiratory muscle training (RMT) and dietary nitrate supplementation can improve exercise tolerance under simulated moderate altitude conditions. Exposure to reduced oxygen availability at altitude places additional strain on the cardiovascular and respiratory systems, which may limit endurance performance. By combining RMT-designed to strengthen the muscles involved in breathing-with nitrate therapy, which enhances nitric oxide availability and vascular function, this study aims to determine whether these interventions independently or synergistically improve oxygen delivery, reduce physiological strain, and enhance exercise performance. The findings will help identify non-pharmacological strategies to improve physical performance and tolerance to hypoxia in both clinical and operational environments.",[110,111,112,72,29,113,114,115],"Healthy Adults","Mechanical Ventilation Dependence","Hypoxia","Dietary Supplement","Nitrate Supplementation","Inspiratory Muscle Training","2025-10-13",{"date":118,"type":45},"2025-10-15",{"date":120,"type":45},"2025-09-01",{"date":122,"type":21},"2028-08-31",{"name":124,"class":52},"Embry-Riddle Aeronautical University"]